A Response To: Letter to the Editor Regarding "Real-World Effectiveness of a Third Dose of MRNA-1273 Versus BNT162b2 on Inpatient and Medically Attended COVID-19 Among Immunocompromised US Adults"
Overview
Overview
Authors
Authors
Affiliations
Affiliations
Soon will be listed here.
References
1.
Sun T, Li L, Mues K, Georgieva M, Kirk B, Mansi J
. Real-World Effectiveness of a Third Dose of mRNA-1273 Versus BNT162b2 on Inpatient and Medically Attended COVID-19 Among Immunocompromised US Adults. Infect Dis Ther. 2024; 13(8):1771-1787.
PMC: 11266318.
DOI: 10.1007/s40121-024-01005-1.
View
2.
Kopel H, Nguyen V, Boileau C, Bogdanov A, Winer I, Ducruet T
. Comparative Effectiveness of Bivalent (Original/Omicron BA.4/BA.5) COVID-19 Vaccines in Adults. Vaccines (Basel). 2023; 11(11).
PMC: 10675676.
DOI: 10.3390/vaccines11111711.
View
3.
Baden L, El Sahly H, Essink B, Kotloff K, Frey S, Novak R
. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2020; 384(5):403-416.
PMC: 7787219.
DOI: 10.1056/NEJMoa2035389.
View
4.
Polack F, Thomas S, Kitchin N, Absalon J, Gurtman A, Lockhart S
. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020; 383(27):2603-2615.
PMC: 7745181.
DOI: 10.1056/NEJMoa2034577.
View
5.
Kirk B, Bush C, Toyip A, Mues K, Beck E, Li L
. Real-world comparative effectiveness of a third dose of mRNA-1273 versus BNT162b2 among adults aged ≥ 65 years in the United States. Vaccine. 2024; 42(25):126113.
DOI: 10.1016/j.vaccine.2024.07.014.
View